graft failure graft versus host disease and impaired hematopoietic stem cell proliferation
Conditions
Interventions
None listed
Sponsors
Swedish Orphan International
Eligibility
Age
No minimum to 99 Years
Inclusion criteria
Inclusion criteria: • The patient must have consented to the use of their clinical data and biological samples for research investigations. • In HSCT cohort: - Patients with underlying: I. non-malignant hematological disease (e.g. autoimmune and metabolic disorders, aplastic anemia, Sickle cell anemia, Fanconi anemia, Diamond-blackfan anemia, thalassemia, osteopetrosis, Wiskott-Aldrich syndrome, severe combined immunodeficiency) or II. malignant disease with higher risk of GF, i.e. Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) with primary induction failure, second partial remission or relapse* Chronic Myeloid Leukemia (CML) in blastic phase (circulating blast or blast above 5% in biopsy)* Non Hodgkin and Hodgkin Lymphoma and multiple myeloma with primary induction failure, second partial remission or relapse, myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) with splenomegaly, myelofibrosis with portal hypertension pre-transplant, MDS/MPD overlap syndromes - and who received allogeneic HSCT and are at higher risk of graft failure based on at least one of the following criteria: I. Having received reduced intensity conditioning (RIC) or non myeloablative conditioning (NMA) combined with a non-malignant disease or having received graft from Bone Marrow (BM) II. Ex vivo T cell depleted graft III. Graft from mismatched unrelated donor or haploidentical donor IV. Graft from Umbilical Cord Blood (UCB) • In the IHSCP cohort: - Patients with IHSCP pre-transplant (e.g. aplastic anemia)
Exclusion criteria
Exclusion criteria: • HLH patients • Body weight
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For HSCT cohort: To investigate the relationship between IFNγ levels and IFNγ activity by measuring CXCL9 levels and the risk of graft failure For IHSCP cohort: To investigate the IFNγ levels and IFNγ activity by measuring CXCL9 levels in patients with impaired HSC proliferation pre-transplant. | — |
Countries
Netherlands
Outcome results
None listed